Orange Book product · Brand (NDA)
LYNKUET
ELINZANETANT
At a glance
Oct 24, 2025
Approved
Brand (NDA)
Application
Not listed
TE code
6
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Oct 24, 2025
8 mo ago
Today
Patent 7683056 expires
Listed drug substance patent expiration.
Sep 15, 2027
in 1 yr 3 mo
Exclusivity ends · NCE
New chemical entity exclusivity (5 years)
Oct 24, 2030
in 4 yr 5 mo
Patent 10195205 expires
Listed method-of-use patent (U-3622) expiration.
May 18, 2036
in 10 yr 1 mo
Patent 10774091 expires
Listed drug product patent expiration.
Mar 13, 2039
in 12 yr 11 mo
Patent 11787820 expires
Listed method-of-use patent (U-3622) expiration.
Mar 13, 2039
in 12 yr 11 mo
Patent 12264164 expires
Listed method-of-use patent (U-3622) expiration.
Mar 13, 2039
in 12 yr 11 mo
Patent 12533358 expires
Listed method-of-use patent (U-4402) expiration.
May 14, 2045
in 19 yr 2 mo
Pharmaceutical detail
Active ingredient
ELINZANETANT
Strength
60MG
Dosage form
CAPSULE
Route
ORAL
TE code
Not listed
Application
NDA 219469
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Marketing exclusivity (1)
- NCENew chemical entity exclusivity (5 years)
Oct 24, 2030
in 4 yr 5 mo
Listed patents (6)
| Patent | Expires | In | Type |
|---|---|---|---|
| 7683056 | Sep 15, 2027 | in 1 yr 3 mo | SubstanceProduct |
| 10195205 | May 18, 2036 | in 10 yr 1 mo | U-3622 |
| 10774091 | Mar 13, 2039 | in 12 yr 11 mo | Product |
| 11787820 | Mar 13, 2039 | in 12 yr 11 mo | U-3622 |
| 12264164 | Mar 13, 2039 | in 12 yr 11 mo | U-3622 |
| 12533358 | May 14, 2045 | in 19 yr 2 mo | U-4402 |
